Literature DB >> 16166283

Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue.

Leena Karenko1, Sonja Hahtola, Suvi Päivinen, Ritva Karhu, Sanna Syrjä, Marketta Kähkönen, Boguslaw Nedoszytko, Soili Kytölä, Ying Zhou, Vesna Blazevic, Maria Pesonen, Hanna Nevala, Nina Nupponen, Harri Sihto, Inge Krebs, Annemarie Poustka, Jadwiga Roszkiewicz, Kalle Saksela, Pärt Peterson, Tapio Visakorpi, Annamari Ranki.   

Abstract

Multicolor fluorescent in situ hybridization (FISH) was used to identify acquired chromosomal aberrations in 12 patients with mycosis fungoides or Sézary syndrome, the most common forms of primary cutaneous T-cell lymphoma (CTCL). The most frequently affected chromosome was 12, which showed clonal deletions or translocations with a break point in 12q21 or 12q22 in five of seven consecutive Sézary syndrome patients and a clonal monosomy in the sixth patient. The break point of a balanced translocation t(12;18)(q21;q21.2), mapped in the minimal common region of two deletions, fine mapped to 12q2. By locus-specific FISH, the translocation disrupted one gene, NAV3 (POMFIL1), a human homologue of unc-53 in Caenorhabditis elegans. A missense mutation in the remaining NAV3 allele was found in one of six cases with a deletion or translocation. With locus-specific FISH, NAV3 deletions were found in the skin lesions of four of eight (50%) patients with early mycosis fungoides (stages IA-IIA) and in the skin or lymph node of 11 of 13 (85%) patients with advanced mycosis fungoides or Sézary syndrome. Preliminary functional studies with lentiviral small interfering RNA-based NAV3 silencing in Jurkat cells and in primary lymphocytes showed enhanced interleukin 2 expression (but not CD25 expression). Thus, NAV3 may contribute to the growth, differentiation, and apoptosis of CTCL cells as well as to the skewing from Th1-type to Th2-type phenotype during disease progression. NAV3, a novel putative haploinsufficient tumor suppressor gene, is disrupted in most cases of the commonest types of CTCL and may thus provide a new diagnostic tool.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166283     DOI: 10.1158/0008-5472.CAN-04-0366

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.

Authors:  L Shan; L Ambroisine; J Clark; R J Yáñez-Muñoz; G Fisher; S C Kudahetti; J Yang; S Kia; X Mao; A Fletcher; P Flohr; S Edwards; G Attard; J De-Bono; B D Young; C S Foster; V Reuter; H Moller; T D Oliver; D M Berney; P Scardino; J Cuzick; C S Cooper; Y-J Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-02-23       Impact factor: 5.554

2.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors:  Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

Review 3.  Navigating the cell: UNC-53 and the navigators, a family of cytoskeletal regulators with multiple roles in cell migration, outgrowth and trafficking.

Authors:  Eve G Stringham; Kristopher L Schmidt
Journal:  Cell Adh Migr       Date:  2009-10-03       Impact factor: 3.405

4.  High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

Authors:  Michael K Kiessling; Patrick A Oberholzer; Chandrani Mondal; Maria B Karpova; Marie C Zipser; William M Lin; Michael Girardi; Laura E Macconaill; Sarah M Kehoe; Charlie Hatton; Lars E French; Levi A Garraway; Gernot Polier; Dorothee Süss; Claus-Detlev Klemke; Peter H Krammer; Karsten Gülow; Reinhard Dummer
Journal:  Blood       Date:  2011-01-05       Impact factor: 22.113

5.  Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death.

Authors:  Paula V Cabrera; Maho Amano; Junya Mitoma; Jessica Chan; Jonathan Said; Minoru Fukuda; Linda G Baum
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

6.  Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies.

Authors:  Caroline Ram-Wolff; Nadine Martin-Garcia; Armand Bensussan; Martine Bagot; Nicolas Ortonne
Journal:  Am J Dermatopathol       Date:  2010-12       Impact factor: 1.533

7.  Aberrant microRNA expression in tumor mycosis fungoides.

Authors:  E Papadavid; M Braoudaki; M Bourdakou; A Lykoudi; V Nikolaou; G Tounta; A Ekonomidi; E Athanasiadis; G Spyrou; C Antoniou; S Kitsiou-Tzeli; D Rigopoulos; A Kolialexi
Journal:  Tumour Biol       Date:  2016-09-13

Review 8.  Fusion genes and their discovery using high throughput sequencing.

Authors:  M J Annala; B C Parker; W Zhang; M Nykter
Journal:  Cancer Lett       Date:  2013-01-29       Impact factor: 8.679

9.  CD158K/KIR3DL2 transcript detection in lesional skin of patients with erythroderma is a tool for the diagnosis of Sézary syndrome.

Authors:  Nicolas Ortonne; Sabine Le Gouvello; Hicham Mansour; Catherine Poillet; Nadine Martin; Marie-Hélène Delfau-Larue; Karen Leroy; Jean-Pierre Farcet; Martine Bagot; Armand Bensussan
Journal:  J Invest Dermatol       Date:  2007-08-16       Impact factor: 8.551

10.  NAV3, a Tumor Suppressor Gene, Is Decreased in Uterine Leiomyoma Tissue and Cells.

Authors:  Jasmine M Aly; Terrence D Lewis; Toral Parikh; Joy Britten; Minnie Malik; William H Catherino
Journal:  Reprod Sci       Date:  2020-01-01       Impact factor: 3.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.